CRMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CorMedix Inc (CRMD) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has shown significant revenue growth in its latest quarter, other financial metrics like EPS and gross margin have declined. The technical indicators are neutral, and there are no significant positive catalysts or strong trading signals to suggest immediate upside potential. Analysts have lowered price targets, though they maintain positive ratings. Given the lack of clear signals and the investor's preference for long-term stability, it is better to hold off on buying this stock right now.
The MACD is slightly positive at 0.0578, but it is contracting, indicating weakening momentum. RSI is neutral at 49.42, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 7.17, with resistance at 7.422 and support at 6.918.
Revenue increased significantly by 312.10% YoY in Q4 2025, showing strong top-line growth.
EPS dropped by 31.82% YoY, and gross margin decreased by 13.30% YoY, indicating potential profitability concerns. Analysts have lowered price targets, and no significant news or trading trends are present.
In Q4 2025, revenue grew by 312.10% YoY to $128.6M, and net income increased by 4.13% YoY to $14M. However, EPS dropped to 0.15 (-31.82% YoY), and gross margin declined to 83.43% (-13.30% YoY).
Analysts have lowered price targets from $15-$22 to $13 while maintaining positive ratings (Outperform/Buy). This reflects cautious optimism but reduced expectations for future performance.
